Unlocking the Future of IBD Management: The Benefits of Biosimilar Infliximab During Pregnancy
Would similarities between researcher infliximab and a biosimilar impact on pregnancy outcomes?
The landscape of pregnancy and neonatal outcomes for women with inflammatory bowel disease (IBD) is rapidly evolving. A recent study has shed new light on the impact of infliximab biosimilars on pregnancy and infant development. Notably, this research comes within the background of a much controvercial decade-long debate on biosimilar safety. Prior to this study, limited data on biosimilar safety during pregnancy had led many to rely on originator infliximab products, even though they were often more expensive and the topics influence HIV treatment access via international aid programs.
Mothers-to-be have different needs, requiring expert care during pregnancy. IBD is a common illness in the peak reproductive years, with Crohn’s disease (CD) and ulcerative colitis (UC) being the largest contributors. Infliximab was traditionally considered to be critical, having been demonstrated safety.
However, due to the recently published studies and finding that Infliximab is a TNF-α biologic… It was well established by prior studies, but those studies had not looked at biosimilars.
Understanding IBD and Pregnancy: A Complex Interplay
IBD peak years just happen to coincide with the peak reproductive years in women, making prenatal management all the more crucial. IBD, encompassing Crohn’s disease (CD) and ulcerative colitis (UC), presents unique challenges during pregnancy. Historically, women with IBD have faced uncertainty regarding the use of biologic therapies during pregnancy.
Prior studies have shown anti-TNF-α biologics such as infliximab to be safe for IBD treatment during pregnancy. However, these studies predominantly featured originator products rather than biosimilars. Until recently, insurance plans in the US offered exceptions allowing for the use of originator infliximabs during pregnancy due to limited data on biosimilar safety and pregnancy outcomes.
Research Outcomes: Infliximab Biosimilars and Pregnancy
A groundbreaking study compared pregnancy and neonatal outcomes as well as developmental milestones for children at one year in 100 women with IBD receiving the infliximab originator and 20 women receiving a biosimilar between 2017 and 2024. Approximately two-thirds of the participants had CD, with 13 (65%) of those treated with biosimilars receiving infliximab-dyyb (CT-P13) and 7 (35%) receiving infliximab-axxq.
Interestingly enough, although the characteristics of the two groups were generally similar, the biosimilars group had a significantly longer median disease duration compared to the reference product group (17 vs 10 years; IQR, 7-21 vs 6-15).
Key Findings and Implications
While adverse pregnancy outcomes other than caesarean section were generally rare and incidence was similar in both groups, the use of infliximab biosimilars did not result in any adverse pregnancy or infant outcomes. Specifically, the study found no significant differences between groups for pre-term birth, small for gestational age, and low birth weight, and infant developmental milestones up to 12 months.
The study concluded that biosimilar therapy does not impact pregnancy complication.
One concerning finding from the study:
Of the women on the biosimilars 63% continued therapy through delivery compared to 87% of the originator. Though are there some unique thresholds to be explored.
However, when you are considering between caesarean births, infant developmental milestones, and maternal and neonatal health, an important consideration is the cost savings that biosimilar medicines provide to IBD patients.
Table: Comparison of Pregnancy and Infant Outcomes
| Outcome Metric | Originator Group (100 women) | Biosimilar Group (20 women) | Similarity |
|---|---|---|---|
| Pre-term Birth | 5% | 5% | No significant difference |
| Small for Gestational Age | 5% | 4% | No significant difference |
| Low Birth Weight | 9% | 5% | No significant difference |
| Caesarean Sections | 35% | 25% | No significant difference |
These results are perhaps the most important from a public health point of view, that analysis has overtaken the United States Healthcare system as Central America where biosimilar saving have impact on government healthcare spend.
In addition, the fact that the receiving group declined due includes minimizing our current economists can translate into healthy outcomes.
Did you know?
Biosimilars are derived from the same biomolecule sequence as their originator counterparts, but are otherwise 100% genetically synthesised.
FAQ: Biosimilar Infliximab and Pregnancy
What are the key findings of the study on infliximab biosimilars during pregnancy?
The study found no significant differences in pregnancy outcomes, such as pre-term birth, small for gestational age, and low birth weight, between women with IBD who received the infliximab originator and those who received a biosimilar. Additionally, infant developmental milestones up to 12 months were also similar between the groups.
Why is managing IBD during pregnancy important?
IBD includes Crohn’s disease (CD) and ulcerative colitis (UC), and these peak reproductive years coincide with the peak years for IBD diagnosis. Effective management during pregnancy is crucial to ensure both maternal and fetal health.
Are there any risks associated with using infliximab during pregnancy?
Prior studies have demonstrated the safety of anti-TNF-α biologics like infliximab for IBD treatment during pregnancy. The recent study on biosimilars further supports their safety, with no increase in infections, differences in vaccine response, or other complications reported in infants.
Can biosimilars be used safely during pregnancy?
Yes, the study found that infliximab biosimilars did not result in any adverse pregnancy or infant outcomes, suggesting that they can be used safely during pregnancy. This is particularly important for shared decision-making and patient counseling.
Pro Tip:
Your IBD specialist/nutitionist can help you weigh the pros and cons of therapy during pregnancy. In addition, it could be vital to consult about the impact of the biological treatments on the polysaccharide content, and thus on affordable feasibility, too.
Explore More on IBD and Pregnancy
With multiple factors affecting the safety of biological treatments, this question becomes more restricted to one of cost. Are biosimilar medicines trumpy? Therefore, there should be discussion on the impact on fertilization success biosimilar medicines should assess the genesis of the probability filter of inflammatory pollution.
If you found this article helpful, explore more about managing IBD during pregnancy and the benefits of biosimilar medications. Engage with us by commenting to share your thoughts, or subscribe to the newsletter for the latest updates and insights relevant to you.
